AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38135187
Drug: SMART (Stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART (Stereotactic MR-guided adaptive radiation therapy)
Trial: 38135320
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day of dark chocolate containing 500 mg total polyphenols and 100 mg vitamin E (n=25)
Trial: 38135371
Drug: Oral decitabine-cedazuridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral decitabine-cedazuridine (35 mg decitabine and 100 mg cedazuridine once daily for 5 days)
Trial: 38135371
Drug: Intravenous decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous decitabine (20 mg/m2)
Trial: 38135371
Drug: Oral decitabine-cedazuridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral decitabine-cedazuridine
Trial: 38135485
Drug: Pudexacianinium (ASP5354)
RxNorm normalized name: Pudexacianinium
DrugBank: Pudexacianinium (DB19161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudexacianinium (ASP5354) 1.0 mg intravenous injection
Trial: 38135485
Drug: Pudexacianinium (ASP5354)
RxNorm normalized name: Pudexacianinium
DrugBank: Pudexacianinium (DB19161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudexacianinium (ASP5354) 3.0 mg intravenous injection
Trial: 38135485
Drug: Pudexacianinium (ASP5354)
RxNorm normalized name: Pudexacianinium
DrugBank: Pudexacianinium (DB19161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudexacianinium (ASP5354) 0.3 mg intravenous injection
Trial: 38137533
Drug: Guideline-oriented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-oriented therapy
Trial: 38140005
Drug: Ped-TMZ oral
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ped-TMZ oral suspension
Trial: 38140005
Drug: TMZ capsules
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TMZ capsules
Trial: 38140184
Drug: Baseline IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline IgG levels ≥ 1.3 µg/mL
Trial: 38140184
Drug: Baseline IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline IgG levels < 1.3 µg/mL
Trial: 38141138
Drug: Iodine-containing multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-containing multivitamin and mineral supplements (≥ 150 μg/day)
Trial: 38141138
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of iodine-containing supplements
Trial: 38141879
Drug: Incidental axillary
RxNorm normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incidental axillary radiation therapy (RT) dose at axilla level I
Trial: 38142044
Drug: Sildenafil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (2 mg/kg/dose enterally every 12 hours for 7 days, 14 doses)
Trial: 38142046
Drug: Family-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Based Treatment with Intensive Parental Coaching (IPC)
Trial: 38142448
Drug: Elevated white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated white blood cell (WBC) count >11 × 10^9/L
Trial: 38142448
Drug: WBC count
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WBC count >12 × 10^9/L (when hematocrit controlled at ≤45%)
Trial: 38142695
Drug: Leterovir (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leterovir (480 mg once daily, adjusted to 240 mg for participants on cyclosporin A) for 200 days
Trial: 38142697
Drug: Standard optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard optimal treatment alone (Control)
Trial: 38142892
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine infusions (3 infusions over 11 days)
Trial: 38144428
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein supplementation (60 g)
Trial: 38144428
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein supplementation (20 g)
Trial: 38145113
Drug: PyroHC (pyrotinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PyroHC (pyrotinib, trastuzumab, and chemotherapy)
Trial: 38145113
Drug: PyroHC (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PyroHC (first-line treatment)
Trial: 39514895
Drug: Computer-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based training for cognitive behavioral therapy (CBT4CBT)
Trial: 38145231
Drug: Multimodal AI
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal AI system using ChatGPT and anterior segment images, smartphone-based, aiming for ≥90% sensitivity and ≥95% specificity for diagnosing and triaging ophthalmic diseases.
Trial: 38145714
Drug: High dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dietary fiber (HFib) intervention with daily snacks high in dietary fiber (10-12 g/day) for 18 weeks.
Trial: 38146256
Drug: Oral anti-coagulants
RxNorm normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-coagulants (OAC)
Trial: 38146256
Drug: In-hospital rhythm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital rhythm control strategies (anti-arrhythmic drug use)
Trial: 38146908
Drug: Aspirin continuation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin continuation within 5 days before surgery (n=269)
Trial: 38146908
Drug: Non-aspirin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin group (stopped aspirin no later than 5 days before surgery) (n=205)
Trial: 38147137
Drug: Isatuximab 10
RxNorm normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isatuximab 10 mg/kg weekly for 4 weeks then every 2 weeks for 8 weeks
Trial: 38147180
Drug: Surgical reconstructive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical reconstructive therapy with adjunctive use of Er:YAG laser
Trial: 38147180
Drug: Surgical reconstructive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical reconstructive therapy without adjunctive use of Er:YAG laser (control group)
Trial: 38147180
Drug: Surgical reconstructive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical reconstructive therapy
Trial: 38147268
Drug: Non-invasive pulsed
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive pulsed radiofrequency (NipRF) therapy applied to the greater occipital nerve (GON)
Trial: 38147281
Drug: Iron-whey-protein microspheres
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-whey-protein microspheres (14 mg daily, 25 mg daily, 50 mg daily) for 12 weeks
Trial: 38147281
Drug: Prior oral
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior oral iron product
Trial: 38147326
Drug: Intensive food-as-medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive food-as-medicine program (providing healthy groceries for 10 meals per week, dietitian consultations, nurse evaluations, health coaching, and diabetes education for 1 year)
Trial: 38147326
Drug: Intensive food-as-medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive food-as-medicine program
Trial: 38147525
Drug: GLPG3312 (Pan-SIK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3312 (Pan-SIK Inhibitor)
Trial: 38147816
Drug: Trastuzumab biosimilar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab biosimilar (HLX02), pertuzumab, and chemotherapy
Trial: 38148064
Drug: Vasopressin 0.2
RxNorm normalized name: VASOPRESSIN 0.2 UNIT/ML/NACL INJ,100ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin 0.2 IU/ml
Trial: 38148064
Drug: Vasopressin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin 0.1 IU/ml
Trial: 38148064
Drug: Vasopressin 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin 0.05 IU/ml
Trial: 38148327
Drug: SCT200 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCT200 monotherapy (from previous phase I study)
Trial: 38148411
Drug: Other chemotherapy
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other chemotherapy regimens
Trial: 38148468
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost (20 μg) for 15 minutes after internal mammary artery harvesting
Trial: 38148468
Drug: Saline inhalation
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline inhalation for 15 minutes after internal mammary artery harvesting
Trial: 38148664
Drug: Blood lactate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood lactate, arginine, and proline metabolism.
Trial: 38148846
Drug: 150 min/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 min/wk of moderate-intensity aerobic exercise (low-dose)
Trial: 38148846
Drug: 300 min/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 min/wk of moderate-intensity aerobic exercise (high-dose)
Trial: 38149073
Drug: Kombucha enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kombucha enriched with inulin (2.53 g/220 mL) and vitamins (B1 - 0.59 mg, B2 - 0.55 mg, B3 - 5.9 mg, B6 - 0.7 mg, folic acid - 81.4 μg/220 mL)
Trial: 38149099
Drug: PyroH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PyroH plus chemotherapy
Trial: 38149099
Drug: HP plus
RxNorm normalized name: Aluris HP Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP plus chemotherapy
Trial: 38149261
Drug: Lived experience
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lived experience of receiving medical treatment for a mental illness
Trial: 38149403
Drug: Intravenous fosphenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosphenytoin 18 mg/kg (high dose)
Trial: 38149403
Drug: Intravenous fosphenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosphenytoin 12 mg/kg (low dose)
Trial: 38149948
Drug: CD30.CAR-T therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD30.CAR-T therapy
Trial: 38150009
Drug: Cocoa flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa flavanols (900 mg/day)
Trial: 38150126
Drug: Merged ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merged ML model utilizing gaze, eye landmarks, head position, and facial landmarks
Trial: 38150232
Drug: Medication for
RxNorm normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication for opioid use disorder (MOUD) treatment offered at intake, throughout incarceration, and upon release.
Trial: 38150232
Drug: Sample contractual
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sample contractual language for medical provider proposals to integrate MOUD treatment.
Trial: 38150256
Drug: Topical 1.62%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1.62% testosterone gel
Trial: 38150260
Drug: High-intensity care
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity care with higher doses of GDMT
Trial: 38150260
Drug: Medium doses
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium doses of GDMT
Trial: 38150260
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of GDMT
Trial: 38150260
Drug: Higher GDMT
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher GDMT doses at week 2
Trial: 38150310
Drug: Remote monitoring,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote monitoring, monthly digital registration of patient-reported outcomes
Trial: 38151376
Drug: Instrumental Activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrumental Activities of Daily Living during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Trial: 38151376
Drug: Basic Activities
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic Activities of Daily Living during hospitalization and at 1, 5, 9, and 13 weeks post-discharge
Trial: 38151388
Drug: epcoritamab monotherapy
RxNorm normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epcoritamab monotherapy
Trial: 38152412
Drug: ixoberogene soroparvovec
RxNorm normalized name: Ixoberogene soroparvovec
DrugBank: Ixoberogene soroparvovec (DB16817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ixoberogene soroparvovec (ixo-vec) gene therapy
Trial: 38152462
Drug: Psilocybin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (10, 20, 30 mg/70 kg)
Trial: 38152697
Drug: Onalespib (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onalespib (260 mg/m) + Paclitaxel (standard dose)
Trial: 38152962
Drug: Reteplase 12+12
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reteplase 12+12 mg
Trial: 38152962
Drug: Reteplase 18+18
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reteplase 18+18 mg
Trial: 38153320
Drug: Repeat treatment
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat treatment courses with Zuranolone
Trial: 38154074
Drug: Prazosin 2.5
RxNorm normalized name: prazosin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 2.5 mg/day for 7 days, then 5 mg/day for 21 days
Trial: 38154083
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin threshold 7.0 g/dL)
Trial: 38154083
Drug: Conservative transfusion
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative transfusion strategy (hemoglobin threshold 5.5 g/dL)
Trial: 38154287
Drug: SPACE-Standard (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPACE-Standard (12 weekly telehealth sessions)
Trial: 38154616
Drug: Ivermectin (0.3-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (0.3-0.4 mg/kg, orally on an empty stomach once daily for three days)
Trial: 38154902
Drug: One of
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of five different single-injection techniques/combination of techniques for regional/neuraxial analgesia
Trial: 38155164
Drug: Multimedia-based hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimedia-based hormone therapy information program (HTIP)
Trial: 38155512
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy for borderline resectable pancreatic cancer
Trial: 38155512
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy for locally advanced pancreatic cancer
Trial: 38155668
Drug: Vibroacoustic pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibroacoustic pulmonary therapy using the 'VibroLung' device in 'ARDS' mode
Trial: 38155668
Drug: Vibroacoustic pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibroacoustic pulmonary therapy using the 'VibroLung' device in 'Pneumonia' mode
Trial: 38155784
Drug: EndoPatch (endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoPatch (endovascular double-disc implant)
Trial: 38155784
Drug: Conventional endovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional endovascular treatment techniques
Trial: 38156601
Drug: Low-dose quadruple
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose quadruple therapy (LDQT)
Trial: 38157190
Drug: Ibrutinib plus
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib plus venetoclax (560 mg ibrutinib and 400 mg venetoclax after a 5-week ramp-up from 20 mg, once daily for up to 104 weeks)
Trial: 38157348
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg IV QID for seven days
Trial: 38157348
Drug: Tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 8 mg/kg (single dose)
Trial: 38157499
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg on day 1 and 75 mg daily on days 2 to 90) plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 21)
Trial: 38157499
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 90)
Trial: 38157986
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg folic acid supplement
Trial: 38157986
Drug: 0 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 μg folic acid supplement (control)
Trial: 38158089
Drug: Octreotide 40-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 40-mg long-acting release intramuscular every 28 days
Trial: 38158089
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (including endoscopic therapy)
Trial: 38158583
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin therapy using a connected insulin pen
Trial: 38158919
Drug: Albuminuria (mild:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuminuria (mild: 10-29 mg/g, moderate/severe: ≥30 mg/g)
Trial: 38159003
Drug: Chitotriosidase (CHIT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitotriosidase (CHIT) level > 171 nmol/h/mL
Trial: 38159266
Drug: Lorpucitinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorpucitinib (30 mg daily, 30 mg every 12 hours, or 75 mg every 12 hours)
Trial: 38159266
Drug: Tofacitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (5 mg every 12 hours)
Trial: 38159266
Drug: Lorpucitinib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorpucitinib (75 mg single dose)
Trial: 38159266
Drug: Lorpucitinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorpucitinib (all doses)
Trial: 38159938
Drug: Secondary cytoreductive
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary cytoreductive surgery followed by platinum based chemotherapy
Trial: 38159946
Drug: Establishment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Establishment of biological sample bank
Trial: 38159958
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) intervention, consisting of 10 sessions.
Trial: 38160049
Drug: HDM sublingual
RxNorm normalized name: ODACTRA 12 SQ-HDM Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM sublingual immunotherapy (SLIT)-tablets
Trial: 38160917
Drug: Evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140 mg subcutaneously every 2 weeks
Trial: 38162283
Drug: Community-based delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based delivery of HIV services including testing, antiretroviral therapy, treatment monitoring and adherence support, family planning, syndromic management of STIs, menstrual health management, condoms, and HIV prevention and general health counselling.
Trial: 38162492
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) alone (standard treatment)
Trial: 38162999
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g sustained-release L-arginine 3 times/d (4.5 g/d) for 4 weeks
Trial: 38163317
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (iFCR with 2-year I-M)
Trial: 38163585
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks for up to 144 weeks (∼3 years)
Trial: 38163912
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for soil-transmitted helminth infections (STH)